Memorial Sloan Kettering Cancer Center immunologist Santosha Vardhana describes the cruelest part of cancer immunotherapy in one sentence: the treatment seems to be working for a patient, and then it ...

CAR-T cell therapies have fundamentally transformed the treatment of several blood and lymph node cancers. However, their use in solid tumors such as liver, breast or lung cancer has so far been ...

Callander, MD, discussed the rationale for a quadruplet regimen being evaluated in patients with relapsed/refractory multiple ...

A joint team of researchers at Bar-Ilan University and the Weizmann Institute has used advanced computational design methods ...

Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer ...

After three patient deaths and the indefinite suspension of several clinical trials, questions exist about the potential future of CAR T-cell research for autoimmune diseases.

Immunotherapy, which uses a patient's immune system to treat disease, has increased survival for some adults and children ...

CAR-T therapy reprograms autologous T cells to recognize leukemia, is generally reserved for relapsed/refractory B-cell ALL, and can provide ongoing immune surveillance when cells persist. Post–CAR-T ...

Maximize ROI by targeting unmet needs with biomarker-led therapies, differentiated safety and rational combinations, guided by uptake, pricing and market access insights.Dublin, Oct. 06, 2026 (GLOBE ...

Abogen Biosciences has entered into a licensing and option agreement with Novartis covering ABO2203 and additional potential ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...